全文获取类型
| 收费全文 | 1418585篇 |
| 免费 | 117161篇 |
| 国内免费 | 3355篇 |
专业分类
| 耳鼻咽喉 | 18553篇 |
| 儿科学 | 46822篇 |
| 妇产科学 | 41280篇 |
| 基础医学 | 201307篇 |
| 口腔科学 | 38250篇 |
| 临床医学 | 127778篇 |
| 内科学 | 285584篇 |
| 皮肤病学 | 33788篇 |
| 神经病学 | 117336篇 |
| 特种医学 | 54499篇 |
| 外国民族医学 | 464篇 |
| 外科学 | 212678篇 |
| 综合类 | 33044篇 |
| 现状与发展 | 3篇 |
| 一般理论 | 511篇 |
| 预防医学 | 111234篇 |
| 眼科学 | 31661篇 |
| 药学 | 99652篇 |
| 1篇 | |
| 中国医学 | 3281篇 |
| 肿瘤学 | 81375篇 |
出版年
| 2021年 | 10236篇 |
| 2019年 | 11928篇 |
| 2018年 | 16861篇 |
| 2017年 | 12885篇 |
| 2016年 | 14510篇 |
| 2015年 | 16291篇 |
| 2014年 | 22969篇 |
| 2013年 | 34038篇 |
| 2012年 | 46276篇 |
| 2011年 | 48827篇 |
| 2010年 | 28664篇 |
| 2009年 | 27509篇 |
| 2008年 | 45129篇 |
| 2007年 | 47632篇 |
| 2006年 | 48248篇 |
| 2005年 | 46711篇 |
| 2004年 | 44559篇 |
| 2003年 | 42366篇 |
| 2002年 | 40858篇 |
| 2001年 | 73493篇 |
| 2000年 | 75005篇 |
| 1999年 | 61705篇 |
| 1998年 | 16206篇 |
| 1997年 | 14555篇 |
| 1996年 | 14689篇 |
| 1995年 | 14873篇 |
| 1994年 | 13482篇 |
| 1993年 | 12675篇 |
| 1992年 | 46197篇 |
| 1991年 | 43889篇 |
| 1990年 | 41870篇 |
| 1989年 | 39894篇 |
| 1988年 | 36472篇 |
| 1987年 | 35670篇 |
| 1986年 | 33168篇 |
| 1985年 | 31590篇 |
| 1984年 | 24022篇 |
| 1983年 | 20182篇 |
| 1982年 | 12322篇 |
| 1981年 | 10880篇 |
| 1979年 | 20885篇 |
| 1978年 | 14711篇 |
| 1977年 | 12182篇 |
| 1976年 | 11432篇 |
| 1975年 | 11709篇 |
| 1974年 | 14124篇 |
| 1973年 | 13673篇 |
| 1972年 | 12760篇 |
| 1971年 | 11596篇 |
| 1970年 | 11031篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
61.
Hallet Julie Look Hong Nicole J. Zuk Victoria Davis Laura E. Gupta Vaibhav Earle Craig C. Mittmann Nicole Coburn Natalie G. 《Gastric cancer》2020,23(3):373-381
Gastric Cancer - Esophagogastric cancer (EGC) is one of the deadliest and costliest malignancies to treat. Care by high-volume providers can provide better outcomes for patients with EGC. Cost... 相似文献
62.
Kerryn W. Reding Aaron K. Aragaki Richard K. Cheng Ana Barac Sylvia Wassertheil-Smoller Jessica Chubak Marian C. Limacher W. Gregory Hundley Ralph D'Agostino Jr. Mara Z. Vitolins Theodore M. Brasky Laurel A. Habel Eric J. Chow Rebecca D. Jackson Chu Chen April Morgenroth Wendy E. Barrington Matthew Banegas Matthew Barnhart Rowan T. Chlebowski 《The oncologist》2020,25(8):712-721
63.
Yi Su Jean W. Woo Timothy C.Y. Kwok 《Journal of the American Medical Directors Association》2019,20(1):83-89
Objectives
To examine the potential added value of a simple 5-item questionnaire for sarcopenia screening (SARC-F) to the Fracture Risk Assessment Tool (FRAX) for hip fracture risk prediction, in order to identify at-risk older adults for screening with dual-energy x-ray absorptiometry (DXA).Design
A prospective cohort study.Setting and participants
Two thousand Chinese men and 2000 Chinese women aged 65 years or older were recruited from local communities and were prospectively followed up for about 10 years.Measures
Areal bone mineral density (BMD) of hip and lumbar spine were measured by DXA at baseline. Ten-year FRAX probability of hip fracture was calculated using the baseline risk factors. Information from the baseline questionnaire was extracted to calculate a modified SARC-F score. The independent predictive values of SARC-F and FRAX questionnaire were evaluated using multivariate survival analysis. The added predictive values of SARC-F to FRAX for pre-DXA screening were examined.Results
During the follow-up, 63 (3.2%) men and 69 (3.5%) women had at least 1 incident hip fracture. SARC-F had an independent value of FRAX for hip fracture risk prediction, with an adjusted hazard ratio [95% confidence interval (CI)] of 1.24 (1.02, 1.52) and 1.15 (0.99, 1.13) in men and women, respectively. Compared with using FRAX, using SARC-F in conjunction with FRAX made the sensitivity for prediction rise from 58.7% to 76.2% in men and from 69.6% to 78.3% in women, with a nondecreased area under receiver operating characteristic curve of 0.67. Prescreening using FRAX in conjunction with SARC-F could save more than half of the DXA assessment than with no prescreening.Conclusions/Implications
SARC-F is associated with a modest increase in hip fracture risk, especially in men. Conjoint evaluation for sarcopenia in addition to FRAX screening may help identify older adults at higher risk of hip fracture for more intensive screening and/or preventive interventions. 相似文献64.
65.
66.
67.
Babiker Hani M. Milhem Mohammed Aisner Joseph Edenfield William Shepard Dale Savona Michael Iyer Swaminathan Abdelrahim Maen Beach C. L. Skikne Barry Laille Eric Tsai Kao-Tai Ho Thai 《Cancer chemotherapy and pharmacology》2020,85(3):621-626
Cancer Chemotherapy and Pharmacology - CC-486 is an oral formulation of azacitidine that allows for extended dosing schedules to prolong azacitidine exposure to malignant cells and maximize... 相似文献
68.
69.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献70.